Merck & Company Inc (MRK)vsRepligen Corporation (RGEN)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
RGEN
Repligen Corporation
$113.11
-3.68%
HEALTHCARE · Cap: $6.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8706% more annual revenue ($65.01B vs $738.26M). MRK leads profitability with a 28.1% profit margin vs 6.6%. MRK appears more attractively valued with a PEG of 3.36. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
RGEN
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+12.9%
Fair Value
$160.09
Current Price
$113.11
$46.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Earnings expanding 160.0% YoY
18.1% revenue growth
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
ROE of 2.4% — below average capital efficiency
6.6% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : RGEN
The strongest argument for RGEN centers on EPS Growth, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : RGEN
The primary concerns for RGEN are Return on Equity, Profit Margin, PEG Ratio. A P/E of 131.5x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while RGEN is a growth play — different risk/reward profiles.
RGEN carries more volatility with a beta of 1.19 — expect wider price swings.
RGEN is growing revenue faster at 18.1% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 45/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Repligen Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?